MENS - Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace.
As of Jun 30, 2026: spot at $2.09, ATM IV 17.5%, net GEX $84.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $142.9M
- Beta
- 2.08
- 52-Week Range
- 1.43-67
- CEO
- Fu-Feng Kuo
- Employees
- 31
- IPO Date
- Jun 17, 2025
- Exchange
- NASDAQ
What MENS Looks Like to Options Traders Today
positive net gamma exposure ($84) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes.
What This Page Covers
The MENS overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked MENS overview questions
- What is MENS?
- MENS is the ticker symbol for Jyong Biotech Ltd. Ordinary Shares, a listed security. Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Listed on NASDAQ. MENS is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the MENS options snapshot look like today?
- As of Jun 30, 2026, the MENS options snapshot shows spot at $2.09, ATM IV 17.5%, net GEX $84, expected move 5.02%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are MENS's key statistics?
- Jyong Biotech Ltd. Ordinary Shares (MENS) carries a market capitalization of $142.9M, beta of 2.08 relative to the broader market, 52-week range of 1.43-67. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does MENS belong to?
- Jyong Biotech Ltd. Ordinary Shares operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare MENS's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the MENS data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).